Cell Source Current Valuation vs. Current Ratio
Cell Source Current Ratio vs. Current Valuation Fundamental Analysis
Cross-company financial ratios help determine Cell Source's valuation standing. Cell Source earns the top ranking in current valuation relative to competitors. It is rated below average in current ratio relative to competitors . For Cell Source, Current Valuation stands at 1,988,340,500 times Current Ratio. Relative valuation compares Cell Source's P/E, P/B, and P/S ratios to sector peers.Cell Current Valuation vs. Competition
Cell Source earns the top ranking in current valuation relative to competitors. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 182.83 Million. Cell Source totals roughly 59.65 Million in current valuation claiming about 33% of market share in Biotechnology space.
Cell Current Ratio vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account all liquid assets, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cell Source |
| = | 59.65 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Cell Source |
| = | 0.03 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least twice current liabilities (i.e., Current Ratio of 2 to 1).
Cell Current Ratio Comparison
Cell Source is currently under evaluation in current ratio relative to competitors.
Cell Source Profitability Projections
Profitability is the engine that drives shareholder value, and Cell Source's profit trends deserve careful attention. Profitability progress for Cell Source combines multiple indicators, where stable trends suggest consistent performance. Profit margin compression during revenue growth may indicate that scale is not translating into efficiency. The patterns visible here help investors assess whether Cell Source's profitability is strengthening or at risk of decline. Recent net income of -5.5 M reflects the bottom-line result of these profitability dynamics.
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
Cell Profitability Driver Comparison
Understanding Cell Source's profitability drivers is essential for assessing the sustainability of its earnings. Unexpected events such as tax policy changes, commodity price shocks, or economic downturns can materially alter the profit outlook and affect long-term investment returns.
Earnings per Share Projection vs Actual
Use Cell Source in pair-trading
Pair trading with Cell Source can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. This framework is most useful when investors want to hedge directional moves caused by sector headlines or broad market pressure.
Cell Source Pair Trading
Cell Source Pair Trading Analysis
Correlation analysis provides context to find suitable substitutes for Cell Source during tax-loss harvesting periods. Selling Cell Source at a loss and immediately repurchasing it would violate IRS wash-sale rules, so a correlated replacement asset is required to maintain portfolio.
Measuring the statistical correlation of Cell Source against other instruments provides context for understanding portfolio diversification. A correlation near zero implies that Cell Source provides genuine diversification benefits, while high positive correlations suggest redundant exposures.
Pair evaluation and Correlation analysis for Cell Source provide hedging context. The context can be applied within sectors, industries, or broader universes.Use Investing Themes to Complement your Cell Source position
Cell Source operates in Healthcare/Biotechnology at 10.61 Million market cap - a thematic view expands this smaller-cap position into a broader portfolio concept. For Cell Source in Biotechnology, the theme workflow defines the investment thesis first, then optimizes which Healthcare assets best express that view at the smaller-cap level.
Did You Try This Idea?
Run Cleaning Thematic Idea Now
Cleaning
Compnanies producing and distributing cleaning products, supplies, and accessories. The Cleaning theme has 38 constituents at this time.
The Cleaning Theme can be deployed as a buy-and-hold allocation or traded actively around individual position volatility.
| View All Next | Launch |
Additional Tools for Cell Pink Sheet Analysis
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash position to determine if your portfolio needs rebalancing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |